LMNX Luminex Dashboard

The mission of Luminex is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. The Company offers a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. Luminex accelerates reliable answers while simplifying complexity and deliver certainty with a seamless experience.

Company profile

Ticker

LMNX

Exchange

NASDAQ

Website

www.luminexcorp.com/

CEO

Nachum Shamir

Incorporated

Delaware

Location

Texas

Fiscal year end

Dec 31

Sector

Professional, Scientific, and Technical Services > Testing Laboratories

Industry (SIC)

Surgical & Medical Instruments & Apparatus

Boston Scientific • Baxter International • Becton, Dickinson And • 3M • Stryker • Teleflex • Resmed • Hill-Rom • Integra Lifesciences • Nuvasive ...

SEC CIK

0001033905

Corporate docs

Articles of Incorporation & Bylaws

IRS number

742747608

LMNX stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Analyzing Luminex's Ex-Dividend Date

23 Mar 21

Luminex Submits Joint SARS-CoV-2 And Flu/RSV Respiratory Panel To FDA For Emergency Use Authorization

10 Mar 21

AUSTIN, Texas, March 10, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced that it has submitted an Emergency Use Authorization application to the U.S. Food and Drug Administration for

The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company

4 Mar 21

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 3)

Luminex Receives FDA Emergency Use Authorization and CE Mark for Expanded NxTAG Respiratory Panel Test Including SARS-CoV-2

4 Mar 21

Luminex Shares Spike To Session High; Bloomberg Report From Feb. 25 Suggested 'DiaSorin Weighs Diagnostics Deal for Luminex'

3 Mar 21

Press releases

Pro users get this 30m faster

Luminex Submits Joint SARS-CoV-2 and Flu/RSV Respiratory Panel to FDA for Emergency Use Authorization

10 Mar 21

Luminex Corporation to Participate at the 2021 Barclays Global Healthcare Conference

9 Mar 21

AUSTIN, Texas, March 9, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced that Homi Shamir, Chairman, CEO & President, and Harriss Currie, Senior Vice President and CFO, plan to participate at

Luminex Receives FDA Emergency Use Authorization and CE Mark for Expanded NxTAG® Respiratory Panel Test Including SARS-CoV-2

4 Mar 21

AUSTIN, Texas, March 4, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a new expanded

Luminex Receives BARDA Funding to Support Development and Validation of Test Combining SARS-CoV-2 and Flu/RSV Respiratory Panel

19 Feb 21

Luminex Corporation Reports Fourth Quarter and Full-Year 2020 Results

8 Feb 21

Calendar

26 Feb 21

11 Apr 21

31 Dec 21

Financial summary

Financial statements Chart LMNX financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Luminex earnings reports.

Recent insider trades

LMNX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
12 Mar 21	Eric Shapiro	Common Stock	Grant	Aquire A	No	No	32.76	12,057	394.99K	46,319
12 Mar 21	Eric Shapiro	Stock Option Common Stock	Grant	Aquire A	No	No	23.09	51,084	1.18M	51,084
12 Mar 21	Nancy Fairchild	Common Stock	Grant	Aquire A	No	No	32.76	12,515	409.99K	46,707
12 Mar 21	Nancy Fairchild	Stock Option Common Stock	Grant	Aquire A	No	No	23.09	53,516	1.24M	53,516
12 Mar 21	Collins Charles J.	Common Stock	Grant	Aquire A	No	No	32.76	14,652	480K	49,503
12 Mar 21	Collins Charles J.	Stock Option Common Stock	Grant	Aquire A	No	No	23.09	64,868	1.5M	64,868
12 Mar 21	Todd C. Bennett	Common Stock	Grant	Aquire A	No	No	32.76	16,788	549.97K	47,579
12 Mar 21	Todd C. Bennett	Common Stock	Payment of exercise	Dispose F	No	No	32.76	2,875	94.19K	30,791
12 Mar 21	Todd C. Bennett	Stock Option Common Stock	Grant	Aquire A	No	No	23.09	72,976	1.69M	72,976
12 Mar 21	Shamir Nachum	Common Stock	Grant	Aquire A	No	No	32.76	61,050	2M	240,655

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

LMNX institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

84.8% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	195	208	-6.3%
Opened positions	31	42	-26.2%
Closed positions	44	35	+25.7%
Increased positions	74	76	-2.6%
Reduced positions	65	62	+4.8%

13F shares	Current	Prev Q	Change
Total value	916.07M	1.11B	-17.2%
Total shares	39.58M	42.13M	-6.1%
Total puts	118.3K	43.6K	+171.3%
Total calls	64K	56.7K	+12.9%
Total put/call ratio	1.8	0.8	+140.4%

Largest owners	Shares	Value	Change
BLK Blackrock	8.16M	$188.75M	+5.9%
Vanguard	5.23M	$120.89M	+2.5%
RGM Capital	2.7M	$62.5M	+7.4%
Dimensional Fund Advisors	1.84M	$42.6M	-6.3%
STT State Street	1.57M	$36.44M	+4.9%
Copeland Capital Management	1.39M	$32.03M	+67.8%
GS Goldman Sachs	1.16M	$26.93M	-7.7%
Acadian Asset Management	1.15M	$26.67M	-20.9%
Millennium Management	963.5K	$22.28M	+2.1%
ATAC Neuberger Berman	958.16K	$22.06M	-0.9%

Largest transactions	Shares	Bought/sold	Change
Redmile	0	-914.11K	EXIT
Select Equity	0	-908.29K	EXIT
Renaissance Technologies	657.24K	-695.8K	-51.4%
Norges Bank	634.16K	+634.16K	NEW
Copeland Capital Management	1.39M	+559.91K	+67.8%
BLK Blackrock	8.16M	+451.62K	+5.9%
Investment Management Of Virginia	0	-447.61K	EXIT
Ophir Asset Management Pty	434K	+434K	NEW
IVZ Invesco	308.68K	-364.53K	-54.1%
Grantham, Mayo, Van Otterloo & Co.	60.47K	-333.93K	-84.7%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Abbott Laboratories • Bio-Rad Laboratories • Perkinelmer • Thermo Fisher Scientific • Danaher • Quidel • Accelerate Diagnostics • Meridian Bioscience • Hologic • Qiagen

Management Discussion

•Consolidated revenue was $417.4 million for 2020, representing a 25% increase over revenue for 2019.
•Assay revenue of $211.9 million for 2020, representing an increase of 60% over 2019.
•Sample-to-answer assay revenue increased for 2020 by $33.2 million, or 49%, from 2019.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: affirmative, affix, affixing, age, Alex, annum, ascertained, avoid, Azar, bankruptcy, BARDA, BBP, benzyl, bifurcated, Britain, Butyl, calendar, carefully, CFTR, Chairman, Commissioner, Concurrent, concurrently, confirmed, congregation, consecutive, cooperation, cope, counterparty, coupon, cov, creditor, culminating, DBP, deal, deeply, default, DEHP, Delegated, deployed, devised, DIBP, Dibutyl, Diisobutyl, disadvantage, disciplinary, discrimination, doubling, drawn, EEE, embrace, empowerment, endeavor, endorsement, engendered, England, enroll, enrollment, ERG, EUA, exert, expeditiously, FAST, FDCA, FDPIC, feel, female, flagship, foregoing, foster, fostering, fractional, fun, GuavaSoft, heater, HHS, Iceland, IgG, inadequacy, incentivize, indenture, insolvency, intervention, Ireland, IRS, justified, justify, justifying, laid, Lehman, letter, Liechtenstein, living, lodge, magnitude, mental, mentoring, misleading, morale, motivate, nasopharyngeal, Northern, Norway, notice, nuclear, pandemic, paramount, parent, PBB, PBDE, phthalate, premium, promptly, proximity, question, racial, radiological, ramping, readability, regrettable, repay, repayment, resume, resurgence, revocation, revoke, revoked, reward, rewarding, rich, RSP, Scotland, Shield, shortly, size, social, sponsorship, stability, strike, strive, subsided, substance, Subtopic, supervisory, surrendered, suspected, swab, Switzerland, systematic, takeover, tandem, thing, thousand, threat, tool, trust, turnover, UK, UKCA, unavailable, uncollectible, unconditional, unfair, unforeseen, unlawful, unpaid, unsecured, unwind, unwinding, usability, variation, vastly, vivo, voluntarily, volunteer, waived, warfare, warrant, weighed, XYP

Removed: accessory, accomplishing, added, analyzing, answer, antibiotic, assemble, attached, attaching, bacteria, bacterial, bear, billion, bind, binding, biochemical, biomarker, blood, bonding, bought, broader, Bulletin, cancer, captured, carry, CDF, children, chronic, clinically, Clostridium, coated, coincide, cold, collaborating, compare, compatible, compound, constituted, contrast, contributor, convenience, customizing, daily, depict, diarrhea, differential, differentiation, displayed, distinctive, dosage, dosing, draft, ease, easy, elderly, emitting, empiric, encoded, enforced, enzymatic, extension, fingerprinting, flame, footprint, fungal, GBS, gold, histocompatibility, hydrogen, hypervirulent, IA, IDbox, identity, immunocompromised, immunologic, ineffective, inexpensive, influenza, inherited, injected, instrumentation, interested, intermediate, ionized, isoC, isoG, iteration, lab, makeup, marketable, MDx, meaningful, memo, Merck, minimizing, mistreated, mixed, mixture, myriad, NanoGrid, naturally, nucleotide, occurring, overuse, owed, pair, patenting, pattern, Physical, placement, Plastic, pneumonia, post, prescribe, prescribing, preserve, presidential, probe, protozoan, provisional, put, refreshed, regimen, reinvestment, remeasurement, request, researcher, retrospectively, revaluation, ribonucleic, room, RP, RTx, SAB, scarcity, scratch, season, shift, signature, simplifying, slim, spectrum, spot, station, stewardship, stool, stoppage, stored, stream, submitting, surface, SYNCTTM, synthetic, technique, template, therapy, tissue, today, topic, transcriptional, true, unnecessary, unpleasant, walkaway, worsening, yeast

From filing 10-K 2020 FY